UC names new medical director of the Medical Intensive Care Unit
R. Duncan Hite, MD, comes to UC from the Cleveland Clinic
R. Duncan Hite, MD, has joined the Division of Pulmonary, Critical Care and Sleep Medicine in the University of Cincinnati (UC) College of Medicine as professor and Mark A. and Alice W. Brown Chair in Internal Medicine and medical director of the Medical Intensive Care Unit (MICU), a position formerly held by David Norton, MD. Hite comes to UC from the Cleveland Clinic where he served as the director of research in the Respiratory Institute, Department of Critical Care, Cleveland Clinic and professor of medicine at Case Western Reserve University.
Hite has a robust laboratory and clinical research program focused on acute lung injury and ICU clinical trials, and is the principal investigator for the Ohio Consortium Clinical Center for the National Health Lung and Blood Institute Prevention and Early Treatment of Acute Lung Injury Network. He also spent 20 years at Wake Forest University School of Medicine where he was section chief for the Wake Forest Baptist Medical Center.
“Dr. Hite’s recruitment will enhance all dimensions of the Critical Care program within UC Medical Center and the College of Medicine,” says Francis McCormack, MD, professor in the Department of Internal Medicine and director of the Division of Pulmonary Critical Care and Sleep Medicine. “As he has done for the Cleveland Clinic, Dr. Hite’s recruitment will make the University of Cincinnati Medical Center MICU a hub for clinical research in the Midwest. He is a role model for our faculty and reinforces the importance of research and education to our overall mission. His appointment opens a new chapter in the distinguished history of critical care medicine and clinical research at this institution.”
Related Stories
What's behind the mysterious rise of migraines?
January 5, 2026
Weather patterns such as extreme heat and storm conditions have been linked to migraine attacks, and research shows those environmental conditions are becoming more common. As National Geographic recently reported, one of the leading theories behind this mysterious rise is that climate change may be playing a role.
Top six 2025 nephrology drug approvals
January 5, 2026
“2025 has been a landmark year for kidney disease therapeutics, marked by a comprehensive slate of FDA approvals covering endothelin-receptor blockade, complement inhibition, GLP-1-based metabolic protection, and B-cell-directed therapy,” Prakash Gudsoorkar, MD, associate professor of clinical medicine at the University of Cincinnati College of Medicine and staff nephrologist at UC Health, recently told MedCentral.
Weight loss drugs help, but not on their own
January 5, 2026
Millions of Americans are on one type of weight loss drug or another, and a University of Cincinnati physician says there are things to know as we enter the new year. Malti Vij, MD, adjunct associate professor in the Department of Internal Medicine and provider at UC Health Primary Care in Mason, recently spoke to 91.7 WVXU News.